MRNA
Moderna, Inc.
Healthcare · Biotechnology · United States · Stock
Score Breakdown
Scored for Speculative Opportunities profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The model score of 28.4 is primarily driven by zeros across profitability (0.0), dividend (0.0), and theme (0.0), which together account for the majority of the possible 100-point range and collectively reflect current losses, no capital return, and limited macro tailwind exposure.
- The momentum sub-score of 14.0 and financial_health sub-score of 8.0 provide the floor that keeps the score from being lower, indicating that while Moderna is loss-making, its balance sheet and recent quarterly trajectory are not in freefall.
- The research label 'Insufficient Data' further suppresses the model's effective confidence, as incomplete metric mapping from the FY2025 10-K filing prevents a full scoring outcome across all ten dimensions.
Why Not Higher
- Profitability scoring at 0.0 is the single largest constraint on a higher composite score — until net and operating margins return to positive territory and are reflected in EDGAR filings, this sub-score will continue to anchor the total score near the bottom of the range.
- The absence of any identified macro theme exposure (theme sub-score 0.0) means Moderna cannot benefit from the model's thematic premium, which rewards companies aligned with four or more tracked structural growth trends.
Data Confidence
6 / 10
Medium — some data gaps
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Moderna, Inc. is a US-based biotechnology company that pioneered the commercial use of mRNA technology, achieving global scale through its COVID-19 vaccine (Spikevax) and now pursuing a broad pipeline spanning respiratory viruses, oncology, rare diseases, and cardiovascular indications. The company's overall model score of 28.4/100 reflects a research candidate in deep financial stress: profitability is scored at 0.0, capturing the sharp deterioration in net and operating margins as COVID-19 vaccine revenues collapsed from their 2021–2022 peaks, while the dividend sub-score of 0.0 confirms the company returns no capital to shareholders. The theme sub-score of 0.0 indicates the available EDGAR filing data did not map Moderna to any of the model's tracked macro themes, further suppressing the composite score. The research tradeoff is stark: Moderna holds a meaningful financial_health sub-score of 8.0, suggesting the balance sheet retains structural resilience — likely from the large cash reserves accumulated during the vaccine supercycle — and a momentum sub-score of 14.0 hints at some sequential quarterly improvement in revenues or margins from a depressed base. However, with the core earnings engine currently loss-making and limited EDGAR data coverage (only 6 of 10 core metrics mapped), the model assigns a 'Insufficient Data' label alongside a Very High risk rating, placing Moderna squarely in the speculative opportunities goal profile.
Plain English
Moderna is the biotech company that made one of the main COVID vaccines using mRNA technology, and it is now trying to build a whole range of new medicines using the same approach. The score of 28.4 out of 100 is low because the company is currently losing money, pays no dividends, and its revenue has fallen sharply since the COVID vaccine boom ended. The Very High risk rating means the research outcome here is highly uncertain — the company could succeed with its next generation of drugs, or it could continue burning through its cash reserves without finding another major hit.
Bull Case vs. Bear Case
Bull Case
- The financial_health sub-score of 8.0 suggests Moderna retains a meaningful balance sheet buffer — likely from accumulated vaccine-era cash — which provides a runway for continued pipeline investment without immediate liquidity pressure.
- The momentum sub-score of 14.0, the highest individual sub-score in the model, signals that quarterly revenue or earnings trends show measurable sequential improvement from a post-COVID trough, indicating the revenue decline may be stabilizing.
- Moderna's mRNA platform, reflected in its growth sub-score of 8.5, positions the company to leverage a validated technology for pipeline assets in RSV, flu, oncology, and rare disease indications, any one of which could materially alter the revenue trajectory if approved.
Bear Case
- The profitability sub-score of 0.0 is a definitive signal that Moderna is currently generating deeply negative net and operating margins, meaning the company is consuming rather than creating financial value from its current revenue base.
- With the dividend sub-score at 0.0 and no FCF payout structure in place, shareholders receive no income component, and the model finds no evidence of free cash flow coverage adequate to support any capital return program in the near term.
- Only 6 of 10 core EDGAR metrics were mappable, resulting in the 'Insufficient Data' research label, which means the model cannot fully assess key dimensions of Moderna's financial profile, introducing additional analytical uncertainty beyond what the scored metrics already reveal.
What Could Change the Picture
Bullish Triggers
- A return to profitability — evidenced by positive net margin and operating margin figures in a future EDGAR 10-K filing — would directly lift the profitability sub-score from 0.0 and could substantially move the composite model score upward.
- Successful commercial launches of next-generation mRNA pipeline products (such as RSV, combination respiratory, or oncology assets) generating meaningful revenue growth would improve the growth sub-score and potentially map the company to one or more macro themes, unlocking the theme sub-score.
Bearish Triggers
- Continued net losses combined with accelerating cash consumption reported in future 10-K filings would erode the financial_health sub-score of 8.0, the current backstop of the composite score, making the overall risk profile materially worse.
- Pipeline setbacks — including clinical failures or regulatory rejections for key mRNA candidates — that are reflected in falling revenues and widening losses in EDGAR filings would push the growth and momentum sub-scores lower, further compressing the already weak composite score.
Red Flags
- The profitability sub-score of 0.0 reflects a company that is loss-making on both a net and operating basis, representing a structural risk if the pipeline does not deliver commercially successful approvals within a reasonable timeframe.
- The theme sub-score of 0.0 indicates the model found no qualifying macro theme exposure in the EDGAR filing data, which may reflect that Moderna's post-COVID revenue base is narrow and not currently aligned with diversified growth catalysts.
- Incomplete data coverage — only 6 of 10 core metrics mapped — means the model's confidence is capped at 6.0/10, and investors should treat the composite score as a partial rather than comprehensive financial assessment.
Risk Profile
Very High RiskThe Very High risk rating for Moderna reflects a combination of current operating losses, a highly concentrated revenue history tied to a single product cycle, and the inherent binary outcomes associated with late-stage clinical pipeline assets that have not yet achieved commercial scale. This profile means research outcomes for Moderna carry a wider-than-average range of financial results, from pipeline-driven recovery to prolonged cash burn.
Key Catalysts to Watch
The primary catalysts to monitor for Moderna are regulatory approval decisions and commercial launch data for its mRNA pipeline programs — particularly respiratory combination vaccines and oncology candidates — which would be the most direct path to restoring positive profitability metrics in future EDGAR filings. Equally important are quarterly earnings disclosures that show whether the momentum sub-score trend of 14.0 is sustained or reverses as COVID-related revenue continues to decline.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.